Mayo临床研究人员利用CRISPR分析BRCA2变异,改进了癌症风险评估。 Mayo Clinic researchers used CRISPR to analyze BRCA2 variants, improving cancer risk assessments.

来自Mayo诊所的研究人员利用CRISPR-Cas9技术分析了BRCA2基因中近7 000种变异物,对91%具有不确定意义的变异物(VUS)进行了分类。 Researchers from the Mayo Clinic used CRISPR-Cas9 technology to analyze nearly 7,000 variants in the BRCA2 gene, classifying 91% of variants of uncertain significance (VUS). 这一突破提高了基因检验的准确性,使得能够对遗传癌症患者进行更精确的癌症风险评估和个性化治疗计划。 This breakthrough improves genetic testing accuracy, enabling more precise cancer risk assessments and personalized treatment plans for patients with hereditary cancers. 调查结果还有助于查明可能受益于诸如PARP抑制剂等有针对性的治疗的病人。 The findings also aid in identifying patients who might benefit from targeted therapies like PARP inhibitors.